Fig. 5: Expression of IL4I1, IDO1 and AHR is upregulated in glioblastoma patients compared to low-grade glioma patients and high levels of IL4I1 are significantly associated with TP53 mutant tumors and poorer survival. | Cell Death & Disease

Fig. 5: Expression of IL4I1, IDO1 and AHR is upregulated in glioblastoma patients compared to low-grade glioma patients and high levels of IL4I1 are significantly associated with TP53 mutant tumors and poorer survival.

From: Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence

Fig. 5

A Expression of IL4I1, IDO1 and AHR in glioblastoma (GBM, n = 153) compared to low-grade glioma patients (LGG, n = 516). Mann–Whitney test was used to analyze statistical significance. B Kaplan–Meier curves depicting the overall survival of GBM or LGG patients expressing high (higher than median) or low (lower than median) levels of IL4I1, IDO1, and AHR. Log-rank Mantel-Cox was used to determine significance.

Back to article page